-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS) Short Interest Update
DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS) Short Interest Update
DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS – Get Rating) saw a large drop in short interest in July. As of July 31st, there was short interest totalling 3,000 shares, a drop of 33.3% from the July 15th total of 4,500 shares. Currently, 0.0% of the company's stock are sold short. Based on an average daily volume of 26,400 shares, the short-interest ratio is presently 0.1 days.
Hedge Funds Weigh In On DA32 Life Science Tech Acquisition
A number of large investors have recently modified their holdings of the company. Exos Asset Management LLC lifted its holdings in shares of DA32 Life Science Tech Acquisition by 4.6% in the 1st quarter. Exos Asset Management LLC now owns 76,951 shares of the company's stock worth $748,000 after purchasing an additional 3,402 shares in the last quarter. Spartan Fund Management Inc. purchased a new stake in DA32 Life Science Tech Acquisition in the 1st quarter valued at $181,000. Ursa Fund Management LLC purchased a new stake in DA32 Life Science Tech Acquisition in the 1st quarter valued at $243,000. Piper Sandler & CO. purchased a new stake in DA32 Life Science Tech Acquisition in the 1st quarter valued at $244,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in DA32 Life Science Tech Acquisition in the 1st quarter valued at $486,000. 60.86% of the stock is currently owned by institutional investors.
Get DA32 Life Science Tech Acquisition alerts:DA32 Life Science Tech Acquisition Price Performance
Shares of DALS remained flat at $9.72 during trading hours on Friday. The company had a trading volume of 3,602 shares, compared to its average volume of 19,005. DA32 Life Science Tech Acquisition has a 12 month low of $9.58 and a 12 month high of $10.26. The stock's 50 day moving average is $9.70 and its 200-day moving average is $9.69.
About DA32 Life Science Tech Acquisition
(Get Rating)DA32 Life Science Tech Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company intends to identify business combination targets in the biotechnology and life science infrastructure sectors.
Further Reading
- Get a free copy of the StockNews.com research report on DA32 Life Science Tech Acquisition (DALS)
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- Look at Honeywell for a Steady and Diversified Stock
- Why Invest in High-Yield Dividend Stocks?
Receive News & Ratings for DA32 Life Science Tech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DA32 Life Science Tech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS – Get Rating) saw a large drop in short interest in July. As of July 31st, there was short interest totalling 3,000 shares, a drop of 33.3% from the July 15th total of 4,500 shares. Currently, 0.0% of the company's stock are sold short. Based on an average daily volume of 26,400 shares, the short-interest ratio is presently 0.1 days.
DA32生命科学技术收购公司(纳斯达克代码:DALS-GET Rating)7月份空头股数股价大幅下跌。截至7月31日,空头股数共有3000股,较7月15日的4500股下降了33.3%。目前,该公司有0.0%的股票被卖空。以日均成交量26,400股计算,目前短息比率为0.1天。
Hedge Funds Weigh In On DA32 Life Science Tech Acquisition
对冲基金参与收购DA32生命科学技术公司
A number of large investors have recently modified their holdings of the company. Exos Asset Management LLC lifted its holdings in shares of DA32 Life Science Tech Acquisition by 4.6% in the 1st quarter. Exos Asset Management LLC now owns 76,951 shares of the company's stock worth $748,000 after purchasing an additional 3,402 shares in the last quarter. Spartan Fund Management Inc. purchased a new stake in DA32 Life Science Tech Acquisition in the 1st quarter valued at $181,000. Ursa Fund Management LLC purchased a new stake in DA32 Life Science Tech Acquisition in the 1st quarter valued at $243,000. Piper Sandler & CO. purchased a new stake in DA32 Life Science Tech Acquisition in the 1st quarter valued at $244,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in DA32 Life Science Tech Acquisition in the 1st quarter valued at $486,000. 60.86% of the stock is currently owned by institutional investors.
一些大型投资者最近调整了对该公司的持股。EXOS Asset Management LLC在第一季度增持了DA32 Life Science Tech收购的股票4.6%。EXOS Asset Management LLC现在拥有76,951股该公司股票,价值748,000美元,上个季度又购买了3,402股。斯巴达基金管理公司在第一季度购买了DA32生命科学技术公司收购的新股份,价值18.1万美元。Ursa Fund Management LLC在第一季度购买了DA32生命科学技术收购的新股份,价值243,000美元。派珀·桑德勒公司在第一季度收购了DA32生命科学技术公司的新股份,价值244,000美元。最后,宾夕法尼亚州联邦公立学校Empls Retrmt Systems在第一季度收购了DA32生命科学技术公司的新股份,价值486,000美元。60.86%的股票目前由机构投资者持有。
DA32 Life Science Tech Acquisition Price Performance
DA32生命科学技术收购价格表现
Shares of DALS remained flat at $9.72 during trading hours on Friday. The company had a trading volume of 3,602 shares, compared to its average volume of 19,005. DA32 Life Science Tech Acquisition has a 12 month low of $9.58 and a 12 month high of $10.26. The stock's 50 day moving average is $9.70 and its 200-day moving average is $9.69.
在周五的交易时段,DALS的股价持平于9.72美元。该公司的成交量为3602股,而其平均成交量为19,005股。DA32生命科学技术收购的12个月低点为9.58美元,12个月高位为10.26美元。该股的50日移动均线切入位在9.70美元,200日移动均线切入位在9.69美元。
About DA32 Life Science Tech Acquisition
关于DA32生命科学技术收购
DA32 Life Science Tech Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company intends to identify business combination targets in the biotechnology and life science infrastructure sectors.
DA32生命科学技术收购公司没有重大业务。它侧重于与一个或多个企业进行合并、资本换股、资产收购、股票购买、重组或相关业务合并。该公司打算确定生物技术和生命科学基础设施领域的业务合并目标。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on DA32 Life Science Tech Acquisition (DALS)
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- Look at Honeywell for a Steady and Diversified Stock
- Why Invest in High-Yield Dividend Stocks?
- 免费获取StockNews.com关于DA32生命科学技术收购(DALS)的研究报告
- 什么是WallStreetBets,他们的目标是什么股票?
- 机构和分析师推动Jack in the Box走高
- 你能猜到哪个电动车股票打败了特斯拉吗?
- 霍尼韦尔看好稳定和多元化的股票
- 为什么要投资高收益股利股票?
Receive News & Ratings for DA32 Life Science Tech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DA32 Life Science Tech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
获得DA32生命科学技术收购日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对DA32生命科学技术收购和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧